A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Summary
The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.
Eligibility
- Age range
- 22+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study. * The participant is ≥22 years of age on the day of signing informed consent. * The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection. * The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy. * The participant with multiple nodules has one nodule that meets the criteria. * The participant has no history of prior malignancy in the chest or has under…
Interventions
- DeviceNovoTTF-200T System
The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
Locations (7)
- Memorial Sloan Kettering Basking Ridge (Consent Only)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only)Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Consent Only)Commack, New York
- Memorial Sloan Kettering Westchester (Consent Only)Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York